Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) Part 3


15 United States sites


2 to 7 Years



Study type








About the study

The Dissemination and Implementation of Stroke Prevention Looking at the Care Environment
(DISPLACE) study is a multi-center, national, National Heart, Lung and Blood Institute
(NHLBI)-funded grant to look at the real-world implementation of stroke prevention guidelines
(STOP Protocol) in which transcranial Doppler (TCD), a measure of cerebral blood vessel
velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia
(SCA). Part 3 of the DISPLACE study is an implementation clinical trial designed to test
novel implementation strategies with the goal of improving adherence and implementation of
stroke screening. 16 of the lowest scoring implementation rates from DISPLACE Part 1 will
participate in DISPLACE Part 3. All original 28 sites from DISPLACE Parts 1 and 2 will
receive a patient and provider educational intervention including a re-branding of the TCD as
“Sickle Stroke Screen” with a new infographic and educational materials. The 16 sites with
moving to Part 3 will be provided a Provider reminder strategy, which is a web based
application designed to remind providers of when patients are due for their Sickle Stroke
Screen. These 16 sites will be randomized and 8 will be given an additional Patient
Communication Strategy. These sites will have a single designed coordinator with whom
patients will communicate with about scheduling, rescheduling, and any other questions
regarding their Sickle Stroke Screen. Upon completion, data will be analyzed to compare those
who have had TCD screenings done appropriately and those who did not as well as the overall
effect of the multi level interventions on the changes in TCD rates.

participation requirements

– Patients with sickle cell anemia (SCA) identified at each institution through
International Classification of Diseases 9/10 (ICD-9/ICD-10) codes and local patient

– Patients must have been seen by the designated institution (documented in medical
record) a minimum of two times in the either inpatient or outpatient setting at the
institution between the years of 01/01/2018-12/31/2019.

– Patients identified will include those currently aged 2-7. Thus children born from
2012 and onward.

– Patients already receiving primary or secondary stroke prevention therapy with CRCT
will be included in registration in Web Data Coordination Unit (WEBDCU) but not
included in PROVIDER MINDER as they do not require ongoing TCD/SICKLE STROKE SCREEN
based on protocol.

participation restrictions

– Patients who do not have SCA

– Patients who were born before 2012 and therefore do not meet age criteria.


  • Little Rock, Arkansas, United States, Arkansas Children's Research Institute, 72202
  • Oakland, California, United States, UCSF Benioff Children's Hospital Oakland, 94609
  • Wilmington, Delaware, United States, Nemours Center for Cancer & Blood Disorders, 19803
  • Washington, District of Columbia, United States, Children's National Medical Center, 20010
  • Washington, District of Columbia, United States, Howard University Hospital, 20060
  • Fort Lauderdale, Florida, United States, Broward Health Medical Center, 33316
  • Gainesville, Florida, United States, University of Florida Health Shands Children's Hospital, 32608
  • Miami, Florida, United States, University of Miami, 33136
  • Atlanta, Georgia, United States, Children's Heathcare of Atlanta, 30322
  • Chicago, Illinois, United States, University of Illinois at Chicago, 60607
  • Saint Louis, Missouri, United States, SSM Health Cardinal Glennon Children's Hospital, 63104
  • Saint Louis, Missouri, United States, St. Louis Children's Hospital, 63110
  • New York, New York, United States, Columbia University Medical Center, 10032
  • Greenville, North Carolina, United States, Vidant Medical Center, 27834
  • Nashville, Tennessee, United States, Vanderbilt Children's Hospital, 37232